Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Anal Cancer Metastatic 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × reolysin × 90 days × Clear all
NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting
122 enrolled
Gastrointestinal

Anal Cancer Metastatic

NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡